The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
AVDL Buyback image

Avadel Pharmaceuticals plc Buyback

OLI recorded this information on 3/7/2017

Company: Avadel Pharmaceuticals plc
Buyback: AVDL buyback
$Amount Authorized: $25,000,000
Buyback Details: Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that the Company's board of directors has authorized the repurchase of up to $25 million of the Company's ordinary shares, represented by American Depository Shares (ADS) which are listed for trading on the NASDAQ Global Market. Repurchases may be made in open-market transactions, block transactions on or off the exchange, in privately negotiated transactions, or through other means as determined by Avadel's board and in accordance with the regulations of the Securities and Exchange Commission.

Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
Open the AVDL Page at The Online Investor »

AVDL — Key Stats (updated 17 hours, 45 minutes ago)
Company Name:  Avadel Pharmaceuticals PLC
Stock buyback:  AVDL buyback
Website:  www.avadel.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AVDL:  3
Total Market Value Held by ETFs:  $741218
Total Market Capitalization:  $1.63B
% of Market Cap. Held by ETFs:  0.05%
 

Open the AVDL Page at The Online Investor (in a new window) »
April 20, 2024  •  4:17 AM Eastern
AVDL — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree AVDL Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Strong Buy (3.90 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
AVDL Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

AVDL Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.